Susanna Naggie, MD

Publications

Alam, I, Brown, K, Donovan, C, Forlenza, J, Lauwers, K, Mah’moud, M, Manch, R, Mohanty, S, Prabhakar, A, Reindollar, R, Sawyerr, G, Slim, J, Tandon, N, Villadiego, S, and Naggie, S. "Effectiveness of Simeprevir-Containing Regimens among Patients with Chronic Hepatitis C Virus in Various Us Practice Settings: The Sonet Study." 2016.

Full Text

Wyles, D, Brau, N, Kottilil, S, Daar, E, Workowski, K, Luetkemeyer, A, Adeyemi, O, Ruane, P, Doehle, B, Huang, K, Osinusi, A, McNally, J, Brainard, D, McHutchison, J, Naggie, S, and Sulkowski, M. "Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study." 2016.

Full Text

Esmat, GE, Shiha, G, Abergel, A, Asselah, T, Kohli, A, Kottilil, S, Ruane, PJ, Naggie, S, Doss, WH, Hahambis, TA, Letterio, C, Natha, M, Kreter, B, Kersey, K, Brainard, D, and Knox, SJ. "INTEGRATED ANALYSIS OF SOF plus RBV OR LDV/SOF FOR THE TREATMENT OF GENOTYPE 4 CHRONIC HCV INFECTION." 2016.

Scholars@Duke

Suhy, D, Patel, K, Kilfoil, G, Wyles, DL, Naggie, S, Lawitz, E, Bradley, S, and Lindell, P. "Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV)." HEPATOLOGY 62, no. 6 (December 2015): 1386A-1386A.

Scholars@Duke

Muir, AJ, and Naggie, S. "Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 13, no. 12 (November 2015): 2166-2172. (Review)

PMID
26192145
Full Text

Rabatin, A, Hashem, M, Townsend, ML, Bryan, WE, Moylan, CA, Choi, SS, and Naggie, S. "Treatment Outcomes of Veterans with Decompensated Cirrhosis Receiving All Oral Direct Acting Antiviral Hepatitis C Therapy." October 2015.

Scholars@Duke

AASLD/IDSA HCV Guidance Panel, . "Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus." Hepatology (Baltimore, Md.) 62, no. 3 (September 2015): 932-954. (Review)

PMID
26111063
Full Text

Rockstroh, J, Cooper, C, Naggie, S, Saag, M, Yang, J, Stamm, L, Pang, P, McHutchison, J, Dieterich, D, and Sulkowski, M. "A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection: the Phase 3 ION-4 study." JOURNAL OF VIRAL HEPATITIS 22 (September 2015): 24-24.

Scholars@Duke

Naggie, S, Cooper, C, Saag, M, Workowski, K, Ruane, P, Towner, WJ, Marks, K, Luetkemeyer, A, Baden, RP, Sax, PE, Gane, E, Santana-Bagur, J, Stamm, LM, Yang, JC, German, P, Dvory-Sobol, H, Ni, L, Pang, PS, McHutchison, JG, Stedman, CAM, Morales-Ramirez, JO, Braeu, N, Jayaweera, D, Colson, AE, Tebas, P, Wong, DK, Dieterich, D, Sulkowski, M, and Investigators, I. "Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1." NEW ENGLAND JOURNAL OF MEDICINE 373, no. 8 (August 20, 2015): 705-713.

Full Text

Younossi, ZM, Stepanova, M, Sulkowski, M, Naggie, S, Puoti, M, Orkin, C, and Hunt, SL. "Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes." The Journal of infectious diseases 212, no. 3 (August 2015): 367-377.

PMID
25583164
Full Text

Pages